Funding, M&A and exec moves matched to your market, from $49/mo billed annually, or $79/mo quarterly.See plans and pricing.See plans →
Spotlight Therapeutics Raises $36.5 Million Series B To Advance A Pipeline Of Cell-Targeted In Vivo Crispr Gene Editing Biologics
PRIVATEMar 22, 2022•over 4 years ago
Amount Raised
$36.5 Million
Round Type
Series B
San Francisco
Description
Spotlight Therapeutics, Inc. (“Spotlight”), a biotechnology company applying new insights to develop cell-targeted in vivo CRISPR gene editing biologics, today announced a $36.5M Series B financing to fuel a drive toward the clinic.
Company Information
Company
Spotlight Therapeutics
Location
San Francisco, California, United States
About
Established in mid-2018, Spotlight Therapeutics is a privately held biotechnology company advancing a pipeline of cell-targeted in vivo CRISPR gene editing therapies. Spotlight's proprietary technology platform TAGE (Targeted Active Gene Editors) is a new class of biologics, CRISPR effectors engineered for direct delivery in vivo, to achieve cell-selective therapeutic genome editing. Spotlight's pipeline is advancing its modular programmable CRISPR effectors towards clinical studies in immuno-oncology, ophthalmic diseases and hemoglobinopathies. The company is headquartered in Hayward, California. For more information, please visit www.spotlighttx.com.
Don't miss Spotlight Therapeutics's next move
Get an email the moment Spotlight Therapeutics raises, hires an exec, or expands, usually minutes after it happens.
One email per event. Unsubscribe anytime.
Related People
Suggested for you
1 contact
Predictive Intelligence
Strategic
ML-powered predictions for Spotlight Therapeutics's next move
San Francisco